Community-acquired pneumonia (CAP) commonly occurs in children. Pediatric hospitalization rates for CAP in the Western world are one to four per 1000 per year, with pneumonia accounting for up to 20% of all pediatric admissions in some settings ([@b1-idmm-25-151]). *Streptococcus pneumoniae* is the most common bacterial cause of pediatric CAP ([@b2-idmm-25-151],[@b3-idmm-25-151]); the introduction of the conjugate pneumococcal vaccine in North America led to a substantial decrease in pneumonia incidence ([@b4-idmm-25-151]). Curiously, subsequent to this, rates of CAP complicated by parapneumonic effusion were observed to increase in Canada and other countries ([@b5-idmm-25-151]--[@b7-idmm-25-151]).

The optimization of the antimicrobial management of CAP with parapneumonic effusion is important because children with this type of infection are often severely ill, requiring admission to hospital, and many require radiological or operative intervention. Choosing empirical antimicrobial therapy is difficult because there are numerous pyogenic bacteria in addition to *S pneumoniae* that cause complicated CAP. These include *Staphylococcus aureus* (both methicillin sensitive and methicillin resistant), group A streptococcus (*Stretococcus pyogenes*), *Streptococcus anginosus* group organisms, *Haemophilus influenzae*, anaerobes and others ([@b8-idmm-25-151]--[@b11-idmm-25-151]). Specific (ie, targeted) antibiotic therapy is not possible in the majority of cases because blood and pleural fluid cultures have been shown to be positive in only 17% to 35% of children ([@b8-idmm-25-151]--[@b13-idmm-25-151]). The low sensitivity of pleural fluid cultures in particular may be due to the fact that antibiotics are often started before pleural fluid specimens are obtained. A recent prospective study that enrolled children with complicated pneumonia presenting to the largest children's hospital in Canada ([@b11-idmm-25-151]) obtained a microbiological diagnosis using culture-based techniques in only 22 of 88 participants. The vast majority of these children were treated with multiple parenteral antimicrobials and more than one-half received vancomycin, yet only a single case of methicillin-resistant *S aureus* empyema was documented.

Molecular techniques may be uniquely well suited to the microbiological diagnosis of complicated CAP because, in contrast to traditional culture-based methods, detection is not predicated on the growth of viable bacteria. However, molecular methods have their own limitations: false-positive results may result from inadequately controlled background contamination ([@b14-idmm-25-151]) or because of very low bacterial concentrations that are not clinically significant but detectable by the assay ([@b15-idmm-25-151]), among other reasons.

The purpose of the present study was to determine whether the microbiological diagnosis of CAP with parapneumonic effusion in children could be improved using nonculture-dependent molecular testing of pleural fluids for bacterial pathogens. Although similar studies have described the results of molecular testing to define bacterial etiology of pediatric parapneumonic effusion in American and European populations ([@b8-idmm-25-151],[@b9-idmm-25-151],[@b12-idmm-25-151],[@b16-idmm-25-151]--[@b19-idmm-25-151]), there is very little in the published literature documenting the Canadian experience with these techniques.

METHODS
=======

Study population
----------------

Children with pneumonia and parapneumonic effusion often receive thoracentesis and/or thoracostomy tube placement for both diagnostic and therapeutic purposes as part of routine care at the Children's Hospital of Eastern Ontario (CHEO, Ottawa, Ontario) and McMaster Children's Hospital (MCH, Hamilton, Ontario). A convenience sample of pleural fluids from children with a diagnosis of complicated pneumonia/empyema/parapneumonic effusion were collected at CHEO (n=47) between January 2009 and March 2011, and at MCH (n=9) between December 2010 and March 2011. The infectious disease service at both hospitals had been involved with all study participants. Any pleural fluid from a patient without a diagnosis of complicated CAP (eg, from neonates with fetal hydrops) was not eligible for inclusion. All children with complicated CAP at both CHEO and MCH during the study period were treated empirically with broad-spectrum intravenous antimicrobials; antibacterials were continued if cultures were negative and rationalized if cultures were positive. Because the present study was retrospective in design, molecular testing results were not available to the treating clinicians. The present study was approved by the Research Ethics Boards of both CHEO and McMaster University (Hamilton, Ontario).

Traditional culture-based sample processing
-------------------------------------------

As part of routine care, all pleural fluids were processed using standard microbiological methods. Aliquots were plated on sheep blood, chocolate and MacConkey agar under aerobic conditions at 37°C and monitored daily for five days. An aliquot was inoculated into thioglycollate broth and aliquots were plated on anaerobic agar media and kept for five days under strict anaerobic conditions; these were also checked daily after being left initially for 48 h. Bacteria were identified using standard laboratory methods. First, Gram stain, colony morphology and growth characteristics on culture media were examined. Based on these results, additional tests were performed. For example, optochin and bile solubility were performed for *S pneumoniae* identification; latex agglutination for group A antigen and bacitracin disk testing were performed for *S pyogenes*; and for streptococcal species other than *S pyogenes* and *S pneumoniae,* an API 20 Strep test (bioMérieux, USA) was performed.

The majority of patients had blood drawn at the study sites and cultures processed using the BacT/Alert platform (bioMérieux, USA).

Nucleic acid extraction
-----------------------

Nucleic acids were extracted from 400 μL of pleural fluid samples. An extraction and amplification control organism that is not associated with human pulmonary infections (*Bacillus atrophaeus*, Steris Life Sciences, USA) was added before extraction ([@b20-idmm-25-151]). Samples underwent bead beating using 0.5 mm beads (ZR BashingBeads, Zymo Research, USA) to break down bacterial cell walls using the Disruptor Genie device (Scientific Industries Inc, USA). Samples were then extracted and purified using an automated NA extraction device (iPrep, Life Technologies, USA), with a final volume of 50 μL. Extraction time was approximately 45 min.

Real-time polymerase chain reaction
-----------------------------------

5′exonuclease polymerase chain reaction (PCR) assays for the major bacterial CAP pathogens were used to test pleural fluid specimens. The PCR targets were the *lytA* gene for *S pneumoniae* ([@b21-idmm-25-151]), the *hpd* gene for *H influenzae* ([@b21-idmm-25-151]), the *nuc* gene for *S aureus* ([@b22-idmm-25-151]), the *spy* gene for *S pyogenes* ([@b23-idmm-25-151]), and the 16S ribosomal RNA gene of both *Streptococcus intermedius* and *Streptococcus constellatus* (two of the three species in the *S anginosus* group) ([@b24-idmm-25-151]).

The limit of detection (LOD) for the assays was determined using serial dilutions of DNA extracted from reference strains of the organisms. The LOD was 100 organisms per PCR reaction for the *S pyogenes*, *S aureus* and *H influenzae* assays; 10 organisms per PCR reaction for the *S pneumoniae* assay; and one organism per PCR reaction for the *S intermedius*/*S constellatus* assay ([Table 1](#t1-idmm-25-151){ref-type="table"}).

Uniplex PCR reaction assays for each target organism were prepared in 20 μL volumes in 96-well PCR plates using an automated liquid handler (Eppendorf 5070, Eppendorf Canada, Canada). A negative control (no template) was performed with each sample. PCR plates were covered with adhesive film (MicroAmp Optical Adhesive Film, Life Technologies Inc, USA) to prevent cross-contamination. PCR was performed using a 96-well fast-cycling block on a ViiA7 thermocyler (Life Technologies Inc, USA) using 40 cycles of two-temperature thermocyling (95°C *×* 3 s and 60°C *×* 30 s), taking approximately 40 min to complete.

Statistical analysis
--------------------

Data were analyzed using STATA version 11.0 (Stata Corp, USA); 95% CIs for proportions were calculated. Differences between PCR diagnostic results and traditional culture-based results were compared using the McNemar exact test.

RESULTS
=======

A total of 56 pleural fluids were analyzed; the majority of patients had received antimicrobials before pleural fluid sampling. Molecular methods detected a pathogen in 46 of 56 samples, yielding an overall positivity rate of 82% (95% CI 70% to 91%). Pneumococcus was detected in 35 of 56 samples (62% \[95% CI 49% to 75%\]). The second most common causative pathogen was group A streptococcus, detected in nine of 56 samples (16% \[95% CI 8% to 28%\]). Two of 56 samples (3.6% \[95% CI 0.4% to 12%) were positive using the *S intermedius*/*S constellatus* assay. No pleural fluids were positive for *S aureus*.

Cultures of blood and pleural fluids detected a pathogen in 14 of 56 patients (25% \[95% CI 14% to 38%\]) -- less than one-third the rate of detection using PCR; this difference was statistically significant (P\<0.0001). Cultures were positive for *S pneumoniae* in eight of 56 patients (14% \[95% CI 6% to 26%\]); this was significantly less sensitive than PCR-based detection (P\<0.0001). Group A streptococcus was cultured from five of 56 patients (9% \[95% CI 3% to 20%\]); although almost twice as many samples were positive using PCR, this difference was not statistically significant (P=0.12). One of 56 cultures (1.8% \[95% CI 0% to 10%\]) grew an organism identified as *S constellatus*. There were no other cultures of blood or pleural fluid positive for any other viridans group streptococci.

Every patient for whom an organism was grown in blood or pleural fluid had the same organism identified by pleural fluid PCR. Three pleural fluid samples had a positive Gram stain but were culture-negative. Two showed Gram-positive cocci in chains (one PCR-positive for group A streptococcus, one PCR-positive for *S pneumoniae*) and one showed Gram-negative cocci. This latter sample was PCR positive for *S pneumoniae*. No pleural fluids or blood cultures were positive for *S aureus* using culture or PCR.

DISCUSSION
==========

In the present series, multiple-target uniplex real-time PCR of pleural fluids clearly outperformed traditional culture-based methods for the microbiological diagnosis of pneumonia with parapneumonic effusion. The benefit of molecular testing relative to culture was found to be greatest for the detection of *S pneumoniae*, the most common cause of bacterial pneumonia in children.

Other investigators have also explored the use of PCR-based techniques for microbiological diagnosis of CAP complicated by parapneumonic effusion ([@b8-idmm-25-151],[@b9-idmm-25-151],[@b12-idmm-25-151],[@b16-idmm-25-151]--[@b19-idmm-25-151]). These studies were performed in different populations in different countries over different time periods with varying baseline pneumococcal vaccination rates. However, their results were consistent with ours in that *S pneumoniae* was shown to be the most common pathogen causing parapneumonic effusion and that molecular detection of this pathogen was demonstrated to be more sensitive than traditional culture-based techniques.

One approach to the detection of multiple pathogens has been broad-range 16S ribsomal RNA PCR. Pathogen detection in culture-negative cases has been shown to be 55% to 65% using this technique ([@b16-idmm-25-151],[@b18-idmm-25-151]), although a more recent study identified a pathogen in only 12% of children with negative blood and pleural fluid cultures ([@b8-idmm-25-151]). Using multiple-target uniplex real-time PCR, we identified a pathogen in 32 of 42 (76%) culture-negative samples; these results are very similar to those of Blaschke et al ([@b9-idmm-25-151]), who used a nested PCR assay and identified bacteria in 73% of cases of culture-negative empyema. In contrast to that study, we did not detect any instances of polymicrobial infection. This discrepancy could be related to differential performance of the molecular assays under study. In other words, our assay may have had insufficient sensitivity or the assay used by Blaschke et al ([@b9-idmm-25-151]) (an 'open' nested assay) may have had suboptimal specificity. Our assay, being a 'closed' assay with multiple uniplex assays run simultaneously, would potentially be more easily adapted to a clinical laboratory setting using the appropriate automation.

Microbiological diagnosis has practical value in that it can facilitate the optimization of antimicrobial therapy. The Infectious Disease Society of America recommends that "empiric therapy with a 3rd-generation parenteral cephalosporin should be prescribed...for infants and children with life-threatening infection, including those with empyema" ([@b25-idmm-25-151]). Our experience, and that of others ([@b11-idmm-25-151]), suggests that ceftriaxone and/or vancomycin are routinely prescribed for children admitted to Ontario hospitals with CAP-associated parapneumonic effusion and, because cultures are often negative, many children with complicated CAP receive broad-spectrum antimicrobial therapy for weeks. Prolonged use of advanced-generation cephalosporins and/or beta-lactam inhibitor combinations is, unfortunately, a concern. Widespread use of these agents has the potential to stimulate the accrual of resistant bacterial clones in the population at large ([@b26-idmm-25-151]).

The solution may be to improve diagnostics and thereby avoid both the under- and overtreatment risks inherent in empirical antimicrobial treatment algorithms. In our series, for example, had molecular testing been available in a timely manner, many patients (ie, those with group A streptococcus isolated from pleural fluids) may have been switched immediately to penicillin G without fear of decreased efficacy. Furthermore, in our region, high-level penicillin resistance (minimum inhibitory concentration ≥8 μ/mL) in *S pneumoniae* is very rare, suggesting that penicillin G or ampicillin could have been used successfully in most of our patients, consistent with Infectious Diseasees Society of America recommendations ([@b25-idmm-25-151]). Molecular methods to reliably determine penicillin susceptibility of pneumococci are not yet available; therefore, future studies should be performed to verify the safety of step-down therapy with ampicillin subsequent to the identification of S *pneumoniae* in populations in which rates of high-level penicillin resistance are low.

There were limitations to the present study. Given that our study population was a convenience sample of pleural fluids, we cannot make inferences about the relative frequency of respiratory pathogens causing pediatric complicated pneumonia in the greater population. We also did not collect data on the immunocompetence of the study participants nor their vaccination records. Regardless, it is interesting that group A streptococcus was the second-most common cause of complicated pneumonia and that we did not find *S aureus* in any of our patients, despite the fact that participants were recruited during the 2009 pH1N1 epidemic. It may be that our PCR assay may have had low sensitivity for *S aureus*; however, unlike *S pneumoniae*, *S aureus* can typically be grown in blood or pleural fluid cultures from the majority of children with empyema ([@b8-idmm-25-151],[@b9-idmm-25-151],[@b16-idmm-25-151],[@b25-idmm-25-151],[@b27-idmm-25-151]); therefore, the fact that no cultures in the present study were positive for *S aureus* suggests that it was present very infrequently, if at all. We note that the LOD of our assays for *S aureus* was the same as it was for group A streptococcus, which we detected quite readily. A second potential limitation was that we used a PCR assay that detected *S intermedius* and *S constellatus*, but not *S anginosus*, the third member of the *S anginosus* group. We selected the assay used for the study based on the knowledge that *S intermedius* and *S constellatus* are significantly more commonly found in pleuropulmonary infections than *S anginosus* ([@b28-idmm-25-151]); nevertheless, it is possible that our overall detection rate would have been higher if we had included a PCR assay targeting *S anginosus*. The *S intermedius/S constellatus* had the lowest LOD because this assay detects a multiple-copy target. Another potential limitation of our findings was that because the LODs for the PCR assays were not identical, organisms for which the LOD was lower may have been detected more readily than other organisms. However, the LOD for the *S pyogenes, H influenzae* and *S aureus* assays were the same, and we detected *S pyogenes* in several cases, suggesting the lack of detection of *H influenzae* and *S aureus* were not likely due to the sensitivity of the assays used for these organisms.

There are barriers to the widespread implementation of molecular testing for the detection of bacterial pathogens. These include concerns about the costs of such testing, the requirement to train laboratory staff to perform these tests and the need for dedicated space to perform testing. However, in clinical situations in which patients have been given antibiotics before specimen collection, such as described in our study of parapneumonic effusion, molecular detection of bacteria was clearly superior to culture-based methods.

SUMMARY
=======

Retrospective use of molecular testing methods enabled us to dramatically increase microbiological diagnosis of CAP with parapneumonic effusion. If available prospectively in a timely manner, this information may enable physicians to select narrower-spectrum and less expensive antimicrobial therapies. We believe future prospective studies assessing the cost effectiveness of molecular assay-guided versus culture-guided management of CAP with parapneumonic effusion would be helpful. In areas where pneumococcal resistance to penicillin is prevalent, such studies could also integrate genotypic identification tests to better predict pneumococcal penicillin susceptibility in addition to pathogen detection ([@b29-idmm-25-151]).
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Real-time polymerase chain reaction 5′ exonuclease assays used for pleural fluid specimen testing

  **Organism**                                             **Target gene**   **Primer (5′ -- 3′)**        **Probe**                      **Ref**                                                                      
  -------------------------------------------------------- ----------------- ---------------------------- ------------------------------ ---------------------------------------------------------------------------- ----
  *Streptococcus pneumoniae*                               *lytA*            ACGCAATCTAGCAGATGAAGCA       TCGTGCGTTTTAATTCCAGCT          AACGCTTGATACAGGGAG^[\*](#tfn2-idmm-25-151){ref-type="table-fn"}^             21
  *Streptococcus pyogenes*                                 *spy*             GCACTCGCTACTATTTCTTACCTCAA   GTCACAATGTCTTGGAAACCAGTAAT     CCGCAACTCATCAAGGATTTCTGTTACCA^[†](#tfn3-idmm-25-151){ref-type="table-fn"}^   23
  *Haemophilus influenzae*                                 *hpd*             GGTTAAATATGCCGATGGTGTTG      TGCATCTTTACGCACGGTGTA          TTGTGTACACTCCGTTGGT^[\*](#tfn2-idmm-25-151){ref-type="table-fn"}^            21
  *Staphylococcus aureus*                                  *nuc*             AAATTACATAAAGAACCTGCGACA     GAATGTCATTGGTTGACCTTTGTA       AATTTAACCGTATCACCATCAATCGCTTT^[†](#tfn3-idmm-25-151){ref-type="table-fn"}^   22
  *Streptococcus intermedius/Streptococcus constellatus*   16S rRNA          TGCAAGTAGAACGCACAGGATG       TGCAGTAAATGTTCTTATGCGGTATTAG   CGCGTAGGTAACCTGCCT^[‡](#tfn4-idmm-25-151){ref-type="table-fn"}^              24
  *Bacillus atrophaeus* (positive control)                 *atpD*            TTGTCTGTGAATCGGATCTTTCTC     CACTTCATTTAGGCGACGATACT        TCCCAATGTTACATTACC^[\*](#tfn2-idmm-25-151){ref-type="table-fn"}^             20
                                                                                                                                                                                                                      

All assays were labelled with fluorescein amidite.

Probe modified from published with use of minor groove binder (MGB);

ZEN internal quencher (Integrated DNA Technologies, USA) used;

MGB probe used in place of dual fluorescence resonance energy transfer probes, forward and reverse primers lengthened at the 3′ end to increase melting temperatures. Ref Reference; rRNA Ribosomal RNA
